NEW YORK, July 8, 2026, 17:04 EDT
- Shares of Alignment Healthcare dropped 16.7% to $20.03 as the company faced a whistleblower complaint from a former executive.
- The company pushed back on the accounting claims and said it plans to defend itself.
- The Medicare Advantage insurer sold off after trading close to a 52-week high.
Alignment Healthcare stock fell Wednesday after a former top executive filed a lawsuit accusing the Medicare Advantage insurer of misreporting expenses to boost profits and pay for executives. The company denies the claims.
The stock finished 16.7% lower at $20.03 and slipped another 1.1% in late trading to $19.81. Shares started at $23.93, touched $24.36, and dropped to $19.50 on the day. Trading hit 15.2 million shares, more than twice the typical 6.0 million. The slide stopped just short of the 52-week peak of $25.12.
That’s what made the lawsuit sting. Alignment has been pitching fast Medicare Advantage growth and margin gains as the case for the stock, promising a switch to profit, so anything that questions expense handling hits right at the numbers investors are buying on.
Former CTO Hakan Kardes filed a lawsuit July 7 in California federal court, claiming Alignment shifted $8 million to $10 million of routine expenses into capital expenditures instead of booking them as operating costs. The suit claims restating those numbers would move 2024 adjusted EBITDA from a positive $1.3 million to a loss between $7 million and $9 million.
Alignment pushed back against the allegations. The company told Becker’s its board’s independent audit committee brought in outside lawyers and an outside accounting firm. That committee found Kardes’ claims had no basis. “Alignment Healthcare believes these allegations are wholly without merit, intends to defend itself vigorously and is confident it will prevail,” the company said. Becker’s Payer Issues | Payer News
The selloff caught the eye of securities lawyers too. Johnson Fistel said it’s looking into whether Alignment followed federal securities law after news broke about the whistleblower lawsuit.
Alignment shares fell 10.6% to $21.50 earlier in the session as fresh allegations hit the stock, Investing.com said. The S&P 500 slipped 0.4%, the Dow dropped 1.1%, and the Nasdaq was little changed. The slide in Alignment looked company-driven, not a broad market or sector move.
Centene picked up 1.47% and Humana added 0.42%. Clover Health dropped 6.8%. The drop in Alignment was steeper than those, pointing to the legal issue over a simple Medicare Advantage move.
The claims hit a business that had been gaining speed operationally. Alignment posted Q1 revenue of $1.24 billion, up 33.3%, and Medicare Advantage membership at roughly 284,800, up 30.9%. The company also lifted the midpoint of its 2026 outlook for membership, revenue, adjusted gross profit and adjusted EBITDA. CEO John Kao in April said Alignment “continues to grow with discipline.” Alignment Healthcare, Inc.
Alignment CFO James Head told investors during the April earnings call the company now sees 2026 membership reaching between 294,000 and 299,000. Head put revenue at $5.16 billion to $5.21 billion and adjusted EBITDA in a $138 million to $163 million range. He said growth in sales and better retention drove the higher membership forecast, even as the last stage of V28, the Medicare payment risk model, is phased in.
The risk now has two sides. The lawsuit might fade if Alignment’s defense works, but if the complaint ends up drawing in regulators, leads to restatements, or hurts investor confidence, the stock’s valuation could get cut again. Analysts and market watchers had already raised concerns on utilization, revenue timing, and execution for 2026, with higher-acuity membership and Medicare rules pressuring margins.
The market has already reacted, while legal steps are just beginning. Next up for Alignment: persuade investors the profit case they signed up for still holds, without forcing a rethink on the numbers.
